Why the study?
Does left ventricular assist device (LVAD) placement improve outcomes in patients with left ventricular noncompaction (LVNC) who fail medical management?
Does left ventricular assist device (LVAD) placement improve outcomes in patients with left ventricular noncompaction (LVNC) who fail medical management?
LVAD placement appears to be a viable therapy for patients with LVNC who fail medical management, either as a bridge to transplant or for long-term management.
Left ventricular noncompaction (LVNC) is a multifactorial structural abnormality of the myocardial wall characterized by prominent trabeculae and deep trabecular recesses. LVNC may present as a congenital or acquired defect characterized by 2 distinct tissue layers: a spongy, noncompacted inner myocardium and a thin, compacted outer myocardium. Patients with LVNC are prone to thromboembolic events, either due to deep trabeculations in the noncompacted myocardium or due to arrhythmias accompanying the defect. There are sparse data concerning treatment options for patients with LVNC who fail medical management. We present 2 such patients with LVNC who, following failed medical management, received a left ventricular assist device (LVAD): one for long-term management and one as a bridge to transplant. Both were managed successfully without thromboembolic events to date. The success of these cases suggests that LVAD placement is a viable therapy in patients with LVNC as a bridge to transplant or as long-term management.
No takes yet. Share an insight, caveat, or question.
Hashemi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: